# Lynx1 Capital Management LP 13F Q2 2026: $866 million

Lynx1 Capital Management LP reported $866 million in 13F securities across 27 positions for the quarter ended June 30, 2026, in a holdings report filed August 13, 2026. Its largest holding was GH Research PLC at $357 million, 41.2% of the reported value. Since Q1 2026 it opened 6 new positions and exited 2.

SpecStream is the live web data engine for teams and agents. It reads the SEC's Form 13F data sets each quarter, and this page is that reading, keyed on the manager's CIK and the security's CUSIP. Ask for the managers or the holdings you track, and each new 13F filing arrives in your sheet, CRM, Slack or agent as the SEC publishes it.

- Quarter: Q2 2026, the quarter ended June 30, 2026
- Reported value: $865,529,222
- Positions: 27
- Filed: August 13, 2026
- Report type: 13F holdings report
- CIK: 1910456
- Form 13F file number: 028-22151
- CRD number: 310301
- Business address: D81 Calle C Suite 301 PMB 1202, Dorado, PR 00646
- SEC filing: [0001910456-26-000004](https://www.sec.gov/Archives/edgar/data/1910456/000191045626000004/0001910456-26-000004-index.htm)
- Investment adviser record: [Form ADV on SpecStream](https://specstream.ai/data/investment-advisers/firm/lynx1-capital-management-lp-310301)

## Top 25 holdings by value

The largest of 27 positions by reported value at the end of the quarter ended June 30, 2026. Put and call options are marked in the class. Change is in shares or principal against the filing for the quarter ended March 31, 2026.

| Issuer | Class | Shares or principal | Value | Change since Q1 2026 |
| --- | --- | --- | --- | --- |
| [GH Research PLC](https://specstream.ai/data/institutional-holders/gh-research-plc-g3855l106) | ORDINARY SHARES | 13,263,288 | $356.5 million | +2,500,000 |
| [Cullinan Therapeutics Inc](https://specstream.ai/data/institutional-holders/cullinan-therapeutics-inc-230031106) | COM | 8,963,500 | $163.2 million | No change |
| [Stoke Therapeutics Inc](https://specstream.ai/data/institutional-holders/stoke-therapeutics-inc-86150r107) | COM | 4,038,404 | $132.1 million | -725,269 |
| [Agios Pharmaceuticals Inc](https://specstream.ai/data/institutional-holders/agios-pharmaceuticals-inc-00847x104) | COM | 3,408,937 | $126.5 million | +797,369 |
| [C4 Therapeutics Inc](https://specstream.ai/data/institutional-holders/c4-therapeutics-inc-12529r107) | COM STK | 7,326,691 | $34.2 million | +327,789 |
| [Korro Bio Inc](https://specstream.ai/data/institutional-holders/korro-bio-inc-500946108) | COM | 1,538,296 | $20.3 million | No change |
| [Tscan Therapeutics Inc](https://specstream.ai/data/institutional-holders/tscan-therapeutics-inc-89854m101) | COM | 8,019,148 | $7.9 million | No change |
| [Precision Biosciences Inc](https://specstream.ai/data/institutional-holders/precision-biosciences-inc-74019p207) | COM NEW | 950,466 | $7.5 million | -34,647 |
| [Neuphoria Therapeutics Inc](https://specstream.ai/data/institutional-holders/neuphoria-therapeutics-inc-64136e102) | COM | 875,328 | $3.8 million | No change |
| [Passage Bio Inc](https://specstream.ai/data/institutional-holders/passage-bio-inc-702712209) | COM NEW | 673,759 | $3.3 million | +50,055 |
| [CG Oncology Inc](https://specstream.ai/data/institutional-holders/cg-oncology-inc-156944100) | COM | 31,391 | $2.2 million | -200 |
| [Pliant Therapeutics Inc](https://specstream.ai/data/institutional-holders/pliant-therapeutics-inc-729139105) | COM | 1,798,070 | $2 million | New |
| [Entrada Therapeutics Inc](https://specstream.ai/data/institutional-holders/entrada-therapeutics-inc-29384c108) | COM | 178,606 | $1.3 million | -33,083 |
| [Vyne Therapeutics Inc](https://specstream.ai/data/institutional-holders/vyne-therapeutics-inc-92941v308) | COM | 1,628,700 | $1.1 million | No change |
| [Proqr Thrapeutics N V](https://specstream.ai/data/institutional-holders/proqr-thrapeutics-n-v-n71542109) | SHS EURO | 521,413 | $969,828 | +452,927 |
| [Traws Pharma Inc](https://specstream.ai/data/institutional-holders/traws-pharma-inc-68232v884) | COM NEW | 559,470 | $471,801 | +544,392 |
| [Foghorn Therapeutics Inc](https://specstream.ai/data/institutional-holders/foghorn-therapeutics-inc-344174107) | COM | 61,588 | $300,549 | New |
| [Denali Therapeutics Inc](https://specstream.ai/data/institutional-holders/denali-therapeutics-inc-24823r105) | COM | 11,658 | $299,844 | -1,868,645 |
| [Xencor Inc](https://specstream.ai/data/institutional-holders/xencor-inc-98401f105) | COM | 18,194 | $292,923 | -518,204 |
| [Absci Corporation](https://specstream.ai/data/institutional-holders/absci-corporation-00091e109) | COM | 21,245 | $246,230 | No change |
| [Werewolf Therapeutics Inc](https://specstream.ai/data/institutional-holders/werewolf-therapeutics-inc-95075a107) | COM | 657,786 | $236,737 | No change |
| [Immatics N.V](https://specstream.ai/data/institutional-holders/immatics-n-v-n44445109) | SHS | 23,236 | $235,381 | -193,737 |
| [Avalo Therapeutics Inc](https://specstream.ai/data/institutional-holders/avalo-therapeutics-inc-05338f306) | COM NEW | 10,100 | $186,648 | New |
| [Bolt Biotherapeutics Inc](https://specstream.ai/data/institutional-holders/bolt-biotherapeutics-inc-097702203) | COM NEW | 30,800 | $118,580 | No change |
| [Nuvation Bio Inc](https://specstream.ai/data/institutional-holders/nuvation-bio-inc-67080n101) | COM CL A | 16,029 | $91,045 | New |

## New positions in Q2 2026

6 positions not in the filing for the quarter ended March 31, 2026.

| Issuer | Class | Shares or principal | Value |
| --- | --- | --- | --- |
| [Pliant Therapeutics Inc](https://specstream.ai/data/institutional-holders/pliant-therapeutics-inc-729139105) | COM | 1,798,070 | $2 million |
| [Foghorn Therapeutics Inc](https://specstream.ai/data/institutional-holders/foghorn-therapeutics-inc-344174107) | COM | 61,588 | $300,549 |
| [Avalo Therapeutics Inc](https://specstream.ai/data/institutional-holders/avalo-therapeutics-inc-05338f306) | COM NEW | 10,100 | $186,648 |
| [Nuvation Bio Inc](https://specstream.ai/data/institutional-holders/nuvation-bio-inc-67080n101) | COM CL A | 16,029 | $91,045 |
| [Eupraxia Pharmaceuticals Inc](https://specstream.ai/data/institutional-holders/eupraxia-pharmaceuticals-inc-29842p105) | COM | 10,000 | $66,100 |
| [Inhibikase Therapeutics Inc](https://specstream.ai/data/institutional-holders/inhibikase-therapeutics-inc-45719w205) | COM NEW | 20,000 | $40,600 |

## Positions exited in Q2 2026

2 positions in the filing for the quarter ended March 31, 2026 and not in this one, with the shares and value reported then.

| Issuer | Class | Shares or principal | Value |
| --- | --- | --- | --- |
| [Design Therapeutics Inc](https://specstream.ai/data/institutional-holders/design-therapeutics-inc-25056l103) | COM | 119,516 | $1.3 million |
| [Ibio Inc](https://specstream.ai/data/institutional-holders/ibio-inc-451033708) | COM NEW | 68,076 | $129,344 |

## Also on SpecStream

- [Lynx1 Capital Management LP Form 13F filing on EDGAR](https://www.sec.gov/Archives/edgar/data/1910456/000191045626000004/0001910456-26-000004-index.htm)
- [Lynx1 Capital Management LP investment adviser record (Form ADV)](https://specstream.ai/data/investment-advisers/firm/lynx1-capital-management-lp-310301)
- [Largest institutional managers by 13F value](https://specstream.ai/data/institutional-holdings)
- [Most widely held securities in 13F filings](https://specstream.ai/data/institutional-holders)

Source: [the SEC's Form 13F data sets](https://www.sec.gov/data-research/sec-markets-data/form-13f-data-sets). Public data published by the US Securities and Exchange Commission (US government work). Managers report these holdings themselves in Form 13F, and the SEC does not check or guarantee them. Form 13F lists long positions in US listed equities, some options and convertible notes held at the end of the quarter, and leaves out short positions, cash, most bonds and holdings below the reporting threshold. Values are market values in US dollars as the manager filed them. A manager can ask the SEC to keep some positions confidential for a time. This page uses SEC data and is not endorsed or certified by the SEC.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Food and beverage consultants in the United States](https://specstream.ai/data/businesses/food-and-beverage-consultants/united-states)
- [Window suppliers in the United States](https://specstream.ai/data/businesses/window-suppliers/united-states)
- [Masonry and concrete contractors in the United States](https://specstream.ai/data/businesses/masonry-and-concrete-contractors/united-states)
- [Cardiology practices in the United States](https://specstream.ai/data/businesses/cardiology-practices/united-states)
- [Ramen restaurants in the United States](https://specstream.ai/data/businesses/ramen-restaurants/united-states)
- [Ferry boat companies in the United States](https://specstream.ai/data/businesses/ferry-boat-companies/united-states)
